Eli Lilly Just Delivered Another Blowout Quarter. Is This Unstoppable Growth Stock Still a Buy?

Eli Lilly reported Q3 revenue up 39% year over year to $24.4 billion, beating analyst estimates, while non-GAAP EPS rose 7% to $7.48, also above estimates. Mounjaro revenue increased 65% to $10.7 billion and Zepbound revenue rose 49% to $5.4 billion; Lilly raised FY2026 revenue guidance to $91 billion–$92 billion from $85 billion–$87 billion. Shares jumped after the beat and raise, though the article notes future GLP-1 competition and pricing pressure as risks.

Analysis

The key investment question is shifting from whether demand exists to how much of it Lilly can convert into durable net sales. Lower realized prices alongside volume growth suggest demand is currently absorbing price concessions, but that is not proof of resilient unit economics: monitor prescription growth against net-price trends and payer access. If volume must accelerate simply to offset worsening rebates or discounts, revenue growth could remain strong while profit conversion disappoints.

The oral launch may expand the addressable patient pool through convenience, but early revenue does not establish how much is incremental versus substitution from Lilly’s injectables. Track new-patient starts, persistence, and product-level net pricing before treating it as a second independent growth engine. Likewise, the article’s low-penetration argument supports a large market, not Lilly’s share of future economics; less-frequent dosing competitors could change adherence and payer preference, but remain a forward catalyst rather than demonstrated displacement.

Near term (days): a beat-and-raise can support momentum, but without valuation and positioning data there is no basis to call the shares attractive after a sharp reaction. Over 1–3 months, focus on prescription/volume trends, realized pricing, access, and any guidance commentary on supply. Over 6–18 months, competitor trial results and Lilly’s pipeline execution matter more than market-size estimates. The concentration of revenue in two products makes downside asymmetric if volume decelerates while price pressure persists. The bullish case is falsified by a sustained volume slowdown, further price erosion not offset by volume, or guidance reductions; acquisition-related adjusted-earnings noise alone is not the key signal.

Key Decisions for Investors

• Do not chase the post-earnings move solely on the beat. If already long, retain exposure only within a risk budget that recognizes concentrated product dependence; valuation and positioning data are needed before recommending an outright add.
• Set a 1–3 month alert for prescription or volume deceleration alongside continued net-price declines, weaker access, or a guidance cut. That combination—not price pressure in isolation—would challenge the growth thesis and warrant reducing exposure.
• Treat Foundayo as a potential market-expansion option, not yet a proven non-cannibalizing growth stream. Verify new-patient mix, persistence, and net sales contribution before underwriting it as additive.
• Track competitor pivotal data and dosing convenience claims against actual efficacy, safety, and payer coverage. Strong comparative data or improved coverage for less-frequent dosing could pressure Lilly’s future share and pricing; absent that evidence, avoid pre-emptive short exposure.